Over-expression of beclin-1 in gallbladder carcinoma and its relationship with prognosis.

Over-expression of beclin-1 in gallbladder carcinoma and its relationship with prognosis.
复制标题

DOI:
10.5114/wo.2014.41395
复制
发表时间:
2014
期刊:
Contemporary oncology (Poznan, Poland)
影响因子:
--
通讯作者:
Zheng Q
Zheng Q
中科院分区:
其他
文献类型:
--
作者:
Chen Y;Yan J;Yu S;Wang X;Zheng Q

文献摘要

被引文献

相似文献

检测胆囊癌组织中beclin-1的表达,分析beclin-1表达与胆囊癌临床病理参数及预后的关系,并探讨微血管密度与beclin-1表达的关系。使用包含118个原发性胆囊肿瘤部位的组织微阵列块。收集临床参数和预后数据。通过免疫组织化学研究分析这些标本中beclin-1的表达,并通过Western印迹法证实。免疫组化染色计数微血管密度。Beclin-1过度表达的总发生率为68.1%(80/118)。Beclin-1过表达与TNM分期、肝转移密切相关。beclin-1的过度表达与患者的年龄、性别、淋巴结转移、肿瘤分化程度无关。Kaplan-Meier法显示,胆囊癌患者中beclin-1的过表达与总生存率无显著性差异。多因素考克斯回归分析显示beclin-1不是胆囊癌的独立预后因素。Beclin-1可能在胆囊癌的发生发展中起一定作用。然而,beclin-1可能不是胆囊癌的有效预后因子。
We determined the expression of beclin-1 in gallbladder carcinoma, analyzed the association of beclin-1 expression with clinicopathologic parameters and prognosis, and investigated the relationship between microvessel density and beclin-1 expression. Tissue microarray blocks containing 118 primary gallbladder tumor sites were used. Clinical parameters and prognostic data were collected. Expression of beclin-1 in these specimens was analyzed by immunohistochemical studies and confirmed by Western blotting. Microvessel density was counted using immunohistochemical staining. The overall rate of over-expression of beclin-1 was 68.1% (80 of 118). Over-expression of beclin-1 was significantly associated with TNM stage and liver metastasis. Over-expression of beclin-1 has no significant relationship with age, sex, lymphatic metastasis, or tumor differentiation. Based on the Kaplan-Meier method, over-expression of beclin-1 showed no significant difference for the overall survival rate in patients with gallbladder cancer. The multivariate Cox regression analysis demonstrated that beclin-1 was not an independent prognostic factor for gallbladder cancer. Beclin-1 might play roles in the development of gallbladder cancer. However, beclin-1 may not be an effective prognostic factor for gallbladder cancer.